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Summary: Plasma SARS-CoV-2 RNA was detected in most hospitalized COVID-19 patients 
including all critically-ill patients, and the levels of RNA are strongly associated with disease 































Background: SARS-CoV-2 viral RNA (vRNA) is detected in the bloodstream of some 
patients with COVID-19 (“RNAemia”) but it is not clear whether this RNAemia reflects 
viremia (i.e., virus particles) and how RNAemia/viremia is related to host immune responses 
and outcomes. 
 
Methods: SARS-CoV-2 vRNA was quantified by ultra-sensitive RT-PCR in plasma samples 
(0.5-1.0 ml) from observational cohorts of 51 COVID-19 patients including 9 outpatients, 19 
hospitalized (non-ICU), and 23 ICU patients, and vRNA levels compared with cross-sectional 
indices of COVID-19 severity and prospective clinical outcomes. We used multiple imaging 
methods to visualize virions in pelleted plasma.  
 
Results: SARS-CoV-2 vRNA was detected in plasma of 100%, 52.6% and 11.1% of ICU, 
non-ICU, and outpatients respectively. Virions were detected in plasma pellets by electron 
tomography and immunostaining. Plasma  vRNA levels were significantly higher in ICU > 
non-ICU > outpatients (p<0.0001); and for inpatient, plasma vRNA levels were strongly 
associated with higher WHO score at admission (p=0.01), maximum WHO score (p=0.002) 
and discharge disposition (p=0.004). A plasma vRNA level >6,000 copies/ml was strongly 
associated with mortality (HR: 10.7). Levels of vRNA were significantly associated with 
several inflammatory biomarkers (p<0.01) but not with plasma neutralizing antibody titers 
(p=0.8). 
Conclusions: Visualization of virus particles in plasma indicates that SARS-CoV-2 
RNAemia is due, at least in part, to viremia. The levels of SARS-CoV-2 RNAemia quantified 
by ultrasensitive RT-PCR correlate strongly with disease severity, patient outcome and 
specific inflammatory biomarkers but not neutralizing antibody titers. 






















The COVID-19 pandemic is the largest public health emergency in modern history, resulting 
from global spread of the newly-emerged coronavirus SARS-CoV-2, a ~30kb single-
stranded positive-sense RNA virus [1, 2]. The respiratory tract epithelial cells are the primary 
target of SARS-CoV-2, and the primary clinical syndrome of COVID-19 is one of upper and 
lower respiratory tract infection. The broad expression of the SARS-CoV-2 receptor ACE2 in 
extrapulmonary tissues could expand viral tropism. Indeed, a wide range of extrapulmonary 
symptoms including loss of smell and taste, vomiting and diarrhea, and neurologic 
impairment have been reported [3]. Detection of SARS-CoV-2 RNA in the gastrointestinal 
tract, endothelium and central nervous system implicates extrapulmonary dissemination as 
an important contributor to disease manifestations severity [4-12]. Current data do not 
suggest that SARS-CoV-2 replicates in peripheral blood cells; however, systemic 
dissemination of virus through the bloodstream to extrapulmonary sites is possible. Aside 
from a central role in disease pathogenesis, viral RNA (vRNA) in blood could represent an 
important indicator of lung barrier breakdown, leading to release of intact virions, virion 
components (proteins and nucleic acids), or infected cell fragments into the bloodstream. 
Although some groups have found that the detection of SARS-CoV-2 RNA in plasma 
(SARS-CoV-2 RNAemia) is associated with severe disease, [13-24] it is unclear whether  
vRNA detected by RT-PCR is in virions and thus reflects viremia. 
Higher levels of serum antibodies to SARS-CoV-2 proteins have been reported in patients 
with more severe disease and who are immunocompetent [25, 26], suggesting that 
antibodies may not protect against severe disease, and thus raises questions about the 
potential benefit of antibody-based therapies in severely ill people. Studies of monoclonal 
antibodies and convalescent plasma therapy have not shown clinical benefit in late stages of 
disease, which provides further evidence that antibodies may fail to clear infection in 



















(casivirimab + indevimab) was shown to modestly improve outcome in hospitalized patients 
who have not generated antibodies to SARS-CoV-2-[33]. In the absence of antibody therapy, 
inconsistent associations between SARS-CoV-2 specific neutralizing antibodies and SARS-
CoV-2 RNAemia have been reported [16, 21, 22, 25, 34], suggesting that neutralizing 
antibody level and function vary between patients and may not prevent viral dissemination in 
some.  
In the current study, we investigated 1) whether RNAemia is an indicator of SARS-CoV-2 
viremia (i.e., virus particles in blood); 2) how often RNAemia can be detected among 
outpatients and hospitalized patients, 3) whether the level of RNAemia is associated with 
clinical outcome including mortality, and 4) the relationship between RNAemia and host 
immune responses including neutralizing antibody and markers of inflammation. 
Results 
Cohort characteristics: 
We enrolled 51 patients with COVID-19, stratified by location of the clinical encounter in 
three groups: i) critically ill patients in the Intensive Care Unit (ICU, n=23), ii) moderately ill 
inpatients hospitalized in dedicated wards for COVID-19 (non-ICU inpatients, n=19), and iii) 
outpatients with mild illness (n=9) [35, 36]. Comparisons of baseline characteristics, 
therapies and outcomes are shown in Table 1. ICU patients had significantly higher 60-day 
mortality than non-ICU inpatients (n=7, 30.4% vs. 0%, p=0.01). ICU patients had higher 
levels of interleukins 6, 8 and 10 (IL-6, IL-8, IL-10), procalcitonin, suppression of 
tumorigenicity (ST)-2 and pentraxin-3 compared to non-ICU inpatients (all p =<0.01, Table 
S1). There was no significant difference in neutralizing antibody titer by plaque reduction 
assay between ICU and non-ICU inpatients (Table 1; p = 0.22). At the time of study there 




















Baseline plasma levels of SARS-CoV-2 RNA and patient outcomes: 
Plasma SARS-CoV-2 RNA was detectable at baseline in all 23 ICU patients, but only 10 of 
19 (52.6%) non-ICU inpatients and in one (11.1%) outpatient (p<0.0001). ICU patients had 
>3,000-fold higher median number of  vRNA copies/ml (3,349 [interquartile range-IQR: 756-
8,408]) compared to non-ICU inpatients (median 1 [1-72] copies/ml, p<0.0001, Table 1 and 
Figure 1A). There was only a moderate, borderline significant association between plasma  
vRNA copies and Ct values from RT-PCR performed on 20 paired nasal swab specimens 
(p=0.052, Figure S2A). We detected a weak non-significant inverse correlation between 
absolute lymphocyte count and plasma  vRNA copies (r=-0.3, p= 0.06, Table S2), but not 
with other available clinical laboratory parameters (Table S2). The small overall sample size 
may have limited the detection of significant correlations. 
Higher plasma  vRNA levels at hospital or ICU admission were significantly associated with 
higher baseline severity of illness (as quantified by a World Health Organization [WHO] 
ordinal scale of > 6) compared with patients having baseline WHO scale < 6 (i.e., mild 
hypoxemia not requiring high flow oxygen or mechanical ventilation) (Figure 1B). Viral RNA 
levels at baseline were also significantly associated with the worst severity of illness (peak 
WHO score) during hospitalization (Figure 1C; p=0.002) as well as hospitalization outcome 
(death vs. discharge to inpatient facility or home care, Figure 1D; p=0.037).  
We performed a rec iver operating characteristic (ROC) curve analysis to define an optimal 
cut-off for  vRNA levels as a predictor of mortality (Figure S1). A cut-off of >6,000 copies/ml 
among all inpatients (ICU and non-ICU) was significantly associated with greater 60-day 
mortality (log-rank p=0.002) and longer hospital stay (log-rank p=0.005) in unadjusted 
Kaplan-Meier curve analyses (Figure 1E and F). The sensitivity and specificity of the cut-off 
for mortality were 67% and 86%, respectively (Figure S1). Similarly, analysis of the receiver 
operator characteristic (ROC) curve with an optimal Youden index (0.56) indicated a 



















proportional hazards models adjusting for the confounding effects of age, sex and treatment 
with corticosteroids, high  vRNA levels were associated with higher hazard ratio for death 
(adjusted HR=10.7, 95% confidence interval=1.49-76.9) and longer time to hospital 
discharge among survivors (adjusted HR=5.12, 95% confidence interval=1.65-15.88). We 
did not find a significant difference in plasma viremia in patients treated 2-3 days before 
sampling with remdesivir or glucocorticoids compared with patients with no treatment. Larger 
studies of the effects of remdesivir, glucocorticoids and other COVID-19 therapies on viremia 
are needed to draw conclusions. 
Plasma contains SARS-CoV-2 virions 
We next sought to characterize the  vRNA present in plasma to determine whether it 
includes intact viral particles. After high speed centrifugation of a subset of plasma samples 
chosen to reflect a wide range of  vRNA levels (6,720 – 304,333 copies/ml) with sufficient 
available sample volume, a median of 76% (56%-80%) of total recovered  vRNA was 
detected in the pellet fraction (Figure 2A) indicating the  vRNA detected is contained within 
or associated with a pelletable structure. Notably, SARS-CoV-2 RNA from positive controls 
(SARS-CoV-2 virions spiked into healthy human donor plasma) was found almost 
exclusively in the pellet fraction (99%) confirming that cell-free SARS-CoV-2 virions are 
pelletable using the same centrifugation conditions. In addition, when free SARS-CoV-2 
RNA was added to SARS-CoV-2-negative plasma prior to centrifugation,  vRNA was not 
recovered in either fraction, indicating that free  vRNA is not stable in plasma and likely does 
not account for the  vRNA detected in the supernatant fraction. When a subset of plasma 
samples was prepared for cyto-spin analysis, immunofluorescence of cyto-spin slides 
stained with two independent SARS-CoV-2-specific antibodies (anti-Nucleocapsid and anti-
Spike) and a platelet marker (anti-CD41) revealed punctate double-positive structures that 
were absent in negative controls prepared from SARS-CoV-2-negative plasma (Figure 2B). 
A mean of 41.5% of double-positive structures co-localized with CD41 (Figure 2B). 



















speed centrifuged plasma samples by electron microscopy and tomographic reconstruction 
(Figure 3A-F). Virions observed ranged from 1-4 per field of view, and presumptive virions 
were found within or in close proximity to presumptive platelets as well as in regions distant 
from identifiable cell fragments (3A-F and Supplemental movies 1-3). Presumptive SARS-
CoV-2 virions were confirmed by immuno-EM using two independent antibodies (Figure 3G). 
Baseline plasma levels of SARS-CoV-2 RNA and host responses:  
Viral RNA levels at baseline were not significantly associated (p=0.8) with neutralizing 
antibody titers by plaque reduction neutralization test (PRNT, Figure 4A). By contrast,  vRNA 
levels were significantly correlated with some plasma biomarkers of innate immunity (IL-6 
(p=0.006), IL-8 (p=0.000096), IL-10 (p=0.0097), ST-2 (p=0.00028)) and inflammation 
(procalcitonin (p=0.0074) and pentraxin-3 (p=.000023)) (Figure 4B and S2B). Notably, these 
biomarkers were significantly different in ICU patients compared to non-ICU inpatients 
(p≤0.1 for all), mirroring the corresponding differences in  vRNA levels (Table S1). These 
findings suggest that dissemination of viral infection is associated with a systemic 
inflammatory host response.  
Longitudinal evolution of plasma levels of SARS-CoV-2 RNA: 
We examined longitudinal changes of  vRNA levels among inpatients with detectable plasma 
RNA at baseline (day 1, n=19) and available follow-up samples (post-enrollment day 5, n=19 
and/or day 10, n=13, Figure S3). Overall, we found a significant decrease in  vRNA levels 
between day 1 and day 5 (p=0.041, Wilcoxon test with Benjamini-Hochberg post hoc 
adjustment), between day 5 and day 10 (p=0.041) and between day 1 and day 10 (p=0.001). 
We further stratified the changes in  vRNA according to 30-day mortality. Among survivors 
(n=13 available samples for day 1, n=13 for day 5 and n=8 for day 10), we found a 
significant decrease in  vRNA levels between day 1 and day 10 (p=0.018). In non-survivors 
(n=6 on day 1, n=5 for day 5 and n=5 for day 10) we did not detect significant change 



















Although the analyses are limited by small sample size, results indicate a modest decrease 
in  vRNA over 10 days in COVID-19 survivors, and no measurable decline in non-survivors. 
Although these data suggest a trend, larger studies are needed to draw conclusions. 
Additionally, viremia provided further prognostic information beyond established clinical risk 
stratification tools (Coronavirus Clinical Characterization Consortium [4C] scores that utilize 
baseline variables for predicting mortality and inpatient deterioration) [37]. In a bivariate 
regression model predicting the worst WHO ordinal scale as a surrogate of inpatient 
deterioration, both viremia (p = 0.002) and 4C deterioration scores (p = 0.007) were 
significant predictors. In a bivariate Cox proportional hazard model for 60-day survival, 
viremia was a significant predictor (p = 0.032) but not the 4C mortality score (p = 0.14).  
DISCUSSION 
Here we show that SARS-CoV-2 RNA is detected in a substantial fraction of hospitalized 
patients, including 100% of patients in the ICU, and that the levels of SARS-CoV-2 RNA 
associate with maximal in-hospital disease severity and 60-day mortality, independent of 
established clinical risk stratification tools. We have also visualized SARS-CoV-2 virions in 
centrifuged plasma pellets using complementary imaging-based approaches. In agreement 
with other recent studies [21, 23], SARS-CoV-2 RNA in plasma associates with some 
established markers of innate immunity and inflammation commonly elevated in patients with 
acute respiratory distress syndrome (IL-6, IL-8, IL-10, procalcitonin and pentraxin-3) but not 
with SARS-CoV-2-specific neutralizing antibody measured by plaque reduction assay. 
Overall, these findings provide new insights into the pathogenesis and outcome of COVID-
19. The strengths of our study include strong evidence that RNAemia is associated with viral 
particles in plasma (i.e., plasma viremia), and absolute quantitation of  vRNA using a SARS-




















Although many studies have shown that the detection of SARS-CoV-2 RNA in plasma 
(SARS-CoV-2 RNAemia) is associated with severe disease and/or unfavorable outcome [13-
24], our study adds unique measures of disease severity to extend these earlier findings, 
such as associations with maximal inpatient WHO disease severity score, discharge location 
(LTAC, SNF or home) and mortality, as well as additional prognostic discrimination beyond  
established, multi-variable clinical predictors of disease severity (I4C). In addition, there has 
been inconsistency in the reported proportion of different patient groups with detectable 
plasma vRNA as well as the levels of plasma  vRNA. Specifically, SARS-CoV-2 RNA has 
been detected in plasma from 35% of patients hospitalized with COVID-19 [13] to 88% of 
critically ill patients [17], with clear trends in each study toward severe disease in those with 
RNAemia. This variability may result from differences in sample types tested (plasma or 
serum) or the type (digital droplet vs. qPCR) and sensitivity of the RT-PCR methods used. 
Here we report detection of  vRNA in 79% of all hospitalized patients, and in 100% of 
critically ill patients (hospitalized, ICU) and 52.6% of moderately ill patients (hospitalized, 
non-ICU). The higher proportion of patients with detectable  vRNA in the current study is 
likely due to the ultrasensitive method used that was based on a qRT-PCR assay of plasma 
HIV-1 RNA that has a 95% limit of detection of 1 copy/ml [38]. Our finding that some viral 
particles associate with platelets suggests that testing of plasma samples retaining platelets 
may be a better sample type than sera for assessing SARS-CoV-2 presence in blood 
because of the removal of platelets from serum with clot formation. Despite the small sample 
size of our cohort, we observed survivors of COVID-19 had statistically significant decreases 
in plasma  vRNA in longitudinal samples, whereas those who succumbed did not have 
significant decreases, although the preliminary nature of this finding requires confirmation in 
additional studies. Similarly, the lack of an observed effect of therapeutic interventions such 
as remdesivir on plasma  vRNA in the current should be confirmed in larger ones. More 
extensive longitudinal sampling from patients across the spectrum of disease severity, 



















interventions, will provide additional insight into the usefulness of SARS-CoV-2 plasma RNA 
as a prognostic marker and a means to guide antiviral therapy.  
This report is the first to show that SARS-CoV-2  vRNA in plasma is associated, at least in 
part, with intact SARS-CoV-2 virions in plasma. We found that  vRNA is more abundant in 
the pelleted fraction of plasma compared to supernatant after high-speed centrifugation. 
While most  vRNA was detected in the pellet fraction and therefore is likely associated with 
pelletable structures (e.g., a virus particle or an infected cell), a fraction was contained in the 
supernatant. Our experimental results suggest that this non-pelletable RNA is unlikely to be 
free  vRNA because free RNA was quickly degraded after spiking into plasma. It could 
represent free  vRNA protected by RNA-binding proteins or viral or cellular fragments, or 
virus particles associated with lipids or lipid-rich structures that alter its density; and, its 
composition may be heterogenous across individuals. Complementary methods including 
immunofluorescence, electron tomography, and immuno-EM confirmed the presence of 
SARS-CoV-2 virions in plasma from the subset of patient samples analyzed. Importantly, we 
were unable to determine if the SARS-CoV-2 virions were infectious because of limited 
sample availability. A recent study was unable to culture SARS-CoV-2 from  vRNA-positive 
sera in Vero E6 cells [20] although optimal methods for culturing SARS-CoV-2 from blood 
have not been defined. To illustrate this point, we show that some SARS-CoV-2 virions 
associate with platelets in blood, thus it is possible that sensitivity of virus culture could be 
improved by using platelet-rich plasma. Future studies should optimize virus culture methods 
from blood and address whether virions in blood are infectious, and whether infected cells (if 
present) in blood are producing infectious virus. It is likely that if SARS-CoV-2 virions in the 
blood are infectious they lead to dissemination of infection to multiple organs [4-12, 39]. 
Whether SARS-CoV-2 directly infects endothelial cells remains controversial [40] and thus 
the mechanisms by which SARS-CoV-2 gains access to the bloodstream and infects 



















Neutralizing antibodies counter viral infections by preventing attachment and entry into cells. 
Clearance of infection that has disseminated to the blood in severely ill people would 
therefore depend, at least partially, on neutralizing antibodies to prevent seeding of 
extrapulmonary organs. Our study is in agreement with others that neutralizing antibody titer 
does not correlate with vRNA levels in blood [16, 21], suggesting that most viremic patients 
have already mounted a neutralizing antibody response, which underscores concern about 
the value of antibody-based therapies in severely ill patients. This is still an unsettled 
question warranting further investigation because a few studies have found an association 
between RNAemia and neutralizing antibody response [22]. A failure of antibody to control 
viremia may be attributable to sub-optimal antibody potency, specificity or function in 
severely ill patients [41, 42]. We did identify a small group of patients with detectable viremia 
and lower neutralizing antibody titers (< 100). It is possible that this patient subgroup could 
benefit from antibody-based therapies. Indeed, recently reported results from the 
RECOVERY trial report a moderate improvement in outcome from treatment with 
monoclonal antibodies (casivirimab + indevimab) in patients who do not have endogenously 
produced antibodies to SARS-CoV-2 in blood [33]. Re-analysis of existing datasets from 
clinical trials following quantification of viremia and pre-treatment levels of endogenous 
neutralizing antibodies may help identify patient subgroups with favorable responses to 
antibody therapy. 
In summary, our findings suggest that SARS-CoV-2 viremia is a strong and independent 
marker of COVID-19 disease severity and outcome. Future investigation should focus on 
whether therapies that prevent or reduce viremia improve clinical outcomes. Clinical studies 
with viremia-targeted outcomes may accelerate development of effective therapies for 
COVID-19, similar to what occurred with antiviral therapy of other viral infections including 





















Study Cohorts:  
Inpatient. From April 4, 2020 through September 4, 2020, we prospectively enrolled 
hospitalized patients with COVID-19 from three hospitals, (UPMC Presbyterian, UPMC 
Shadyside and UPMC East) in an observational cohort study (protocols STUDY19050099 
and STUDY20040036). We included patients aged 18-90 years old, who were diagnosed 
with SARS-CoV-2 infection by a positive nasopharyngeal swab quantitative polymerase 
chain reaction (qPCR) test, and had acute illness consistent with COVID-19 as the main 
reason for hospitalization. Patients were hospitalized either in an intensive care unit (ICU) or 
in a dedicated hospital ward (non-ICU setting) for COVID-19. 
Outpatient. Beginning March 11, 2020, participants ages 2 and older with confirmed or 
suspected SARS-CoV-2 infection were identified by provider-referral or self-referral in the 
outpatient clinic or community setting, and enrolled into the Molecular and Epidemiological 
Study of Suspected Infection (MESSI, Pro00100241), as described previously [46]. The 
objective of the MESSI observational study is to enroll subjects with suspected SARS-CoV-2 
infection, and to collect clinical and symptom information and bank biological samples for 
research use. All outpatient subjects included in this study remained in outpatient or at home 
setting throughout the course of COVID-19 illness. SARS-CoV-2 virus testing was performed 
by quantitative RT-PCR from nasopharyngeal swabs. COVID-19-positive subjects included 
in these analyses demonstrated SARS-CoV-2 qPCR-positive result during acute infection. 
IRB Approvals. All research protocols were approved by the relevant institutional IRBs, and 
were performed in accordance with the Declaration of Helsinki. Written informed consent 




















Clinical Data Extraction and Definitions: 
We classified patients based on the location of delivery of care at the time of patient 
enrollment and biospecimen acquisition into an ICU group (i.e., critically-ill patients requiring 
mechanical ventilation or high levels of oxygenation support), a non-ICU group (moderately-
ill inpatients) and an outpatient group of mildly symptomatic subjects. For ICU patients, we 
considered the date of ICU admission the baseline timepoint, whereas for non-ICU patients 
the date of hospital admission was considered baseline. We recorded baseline 
demographics, COVID-19 severity by the WHO 10-point ordinal scale (baseline and peak 
during hospitalization), administered COVID-19-targeted therapies, duration of mechanical 
ventilation for intubated patients, length of hospital stay and final outcome of hospitalization 
(death vs. discharge to home care or inpatient facility). When available, we also recorded the 
cycle threshold (Ct) value of the nasopharyngeal swab qPCR that was used to establish the 
clinical diagnosis of COVID-19 as a surrogate of viral load in the respiratory tract. We utilized 
baseline clinical and laboratory variables for estimation of the 4C scores for risks of mortality 
and inpatient deterioration. Clinical laboratory parameters of interest (white blood cell count, 
absolute lymphocyte count, platelets, D-dimer, ferritin and lactate dehydrogenase), were 
provided when available as part of standard clinical care. We obtained laboratory values 
from the electronic medical record when corresponding clinical blood draws had occurred on 
the same date of research sample acquisition. When clinical laboratory parameters were not 
available on that same date we utilized available clinical laboratory results for up to two days 
before or after the same date of research sample acquisition.  
Experimental analyses:  
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Table 1: Descriptive characteristics of outpatients and inpatients with COVID19, stratified by moderately-ill (hospitalized, non-ICU) 
vs. critically-ill (ICU). Non-parametric test comparisons were performed with Wilcoxon and Fisher’s exact test for continuous and 
categorical variables, respectively. 
 
Outpatient Inpatient, non-ICU Inpatient, ICU 
p-
value* 




      
Age (median [IQR]) 35.0 [26.9, 52.4] 60.0 [52.0, 66.0] 65.0 [57.5, 75.5] 0.11 
Males, n (%) 2 (22.2)  9 (47.4)  16 (69.6)  0.21 
Caucasian race, n (%) 4 (44.4) 15 (78.9)  12 (52.2)  0.11 
BMI (median [IQR]) 
 
31.1 [29.0, 36.6] 33.8 [27.0, 39.4] 0.52 
Diabetes, n (%) 
 
4 (21.1)  7 (31.8)  0.50 
COPD, n (%) 
 
2 (10.5)  6 (26.1)  0.26 
Immunosuppressed host, n (%) 
 
2 (10.5)  4 (17.4)  0.67 
Resident of nursing facility, n (%)  0 (0) 1 (5.3)  4 (17.4) 0.36 
Detectable plasma SARS-CoV-2 
RNA, n (%) 
1 (11) 10 (53) 23 (100) 
 
SARS-COV-2 RNA copies (median 
[Range]) 
1 [<1, 5] 1 [<1, 918] 3349 [32, 225,320] <0.0001 
PRNT titer (median [IQR]) 
 
647.7 [23.4, 2407.5] 2487.0 [287.8, 3695.8] 0.22 
COVID19 Treatments 
 
      


















Convalescent plasma, n (%) 0 (0)  2 (10.5)  10 (43.5)  0.04 
Glucocorticoids, n (%) 0 (0) 10 (52.6)  15 (65.2)  0.33 
Illness Severity and Outcome 
 
      
Baseline WHO scale (median 
[IQR])  
5.0 [4.0-5.0] 7.0 [6.0-8.0] <0.001 
Worst WHO scale during 
hospitalization (median [IQR])  
5.0 [5.0-5.0] 9.0 [6.5-10.0] <0.001 






















Figure 1: SARS-CoV-2 RNA levels in plasma are associated with disease severity and 
outcome. Plasma SARS-CoV-2 RNA levels (copies/ml) by location of clinical care at baseline 
(A), severity of illness by WHO ordinal scale at baseline (B), and worst WHO scale during 
hospitalization (C) for outpatient (n=9), inpatient non-ICU (n=19) and inpatient ICU (n=24). 
Kaplan-Meier curves for time to discharge from hospital admission (D) and 60-day survival (E) 
for inpatients (both ICU and non-ICU) stratified by high (>6,000 copies/ml) vs. low (=<6,000 
copies/ml) initial viral RNA level. Plasma SARS-CoV-2 RNA levels (copies/ml) by outcome of 
hospitalization among inpatients (F). Patients with undetected SARS-CoV-2 RNA in plasma are 
represented by open circles and graphed as one half the LLOD. 
Figure 2: SARS-CoV-2 RNA in plasma includes a pelletable fraction containing virus particles. 
Percent of total recovered SARS-CoV-2 RNA detected in the pellet or supernatant fractions of 
spiked-in control SARS-CoV-2 virus or plasma from 3 inpatients with COVID-19 centrifuged at 
21,000 x g for 2 hours (A). Immunofluorescence of cytospin slides prepared from plasma of 
COVID-19 inpatients PID3 (upper) and PID2 (lower) including the platelet marker CD41 (upper, 
white; lower, blue), and SARS-CoV-2 S and N proteins (upper, red and green or yellow for 
colocalization; lower, white) (B). 
Figure 3. SARS-CoV-2 RNA in plasma includes a pelletable fraction containing SARS-CoV-2 
virus particles.  Electron micrographs of pelleted fraction of plasma from two independent 
COVID-19 inpatients, PID2 (A, B and G) and PID1 (C-F). Montaged overview of a field of 
platelets surrounded by amorphous plasma material and large clusters of fibrils, possibly 
collagen (A and B). Tomographic reconstruction of the region indicated by the square in upper 
left, showing a single presumptive SARS-CoV-2 virion within a membrane-bound compartment 



















membrane bilayer and distinct surface spikes (B, red dots). 2D overview image of three platelets 
(C). High-magnification tomographic slice of a presumptive SARS-CoV-2 virion within an 
enclosed compartment of a platelet (D). Tomogram detail of a group of vesicles. Two spherical 
structures conform to presumptive SARS-CoV-2 virions (E, red arrowheads). Tomogram of a 
second platelet within the field, similarly surrounded by small vesicles (F). Tomogram detail of 
the area indicated by the rectangle in F, showing 3 presumptive virions adjacent to the platelet 
(F, inset). Presumptive virions were identified as described (Methods) and by comparisons with 
analogous EM of SARS-CoV-2–infected cultured cells. Immuno-EM image from pelleted fraction 
of plasma of PID2; presumptive SARS-CoV-2 virion labeled with anti-N (large 15 nm) gold 
particle and anti-S (smaller 10 nm) gold particles (G). 
Figure 4: Plasma SARS-CoV-2 RNA levels are not significantly correlated with SARS-CoV-2-
specific neutralizing antibody levels but are correlated with multiple host-response inflammatory 
biomarkers in hospitalized patients. Correlations between SARS-CoV-2 RNA levels and anti 
SARS-CoV-2 neutralizing antibodies measured by plaque reduction neutralization titer (PRNT) 
assay (A), or the inflammatory biomarkers IL-8, IL-6, procalcitonin, suppressor of tumorigenicity 
2 (ST-2), IL10 and pentraxin 3 measured in the plasma of COVID-19 inpatients (B). Red dots 
represent non-ICU patients and blue dots represent ICU patients. Undetected values are 
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